Refine by
Patient Sample Articles & Analysis: Older
58 news found
The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio’s POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary workflow to process patient samples. It is well ...
By offering a comprehensive selection of Circulatory System Tissue Microarrays with diverse patient samples and disease states, CD BioSciences aims to empower researchers to gain deeper insights into these critical areas of human health and conduct more efficient and comprehensive studies. ...
The iGEM (International Genetically Engineered Machine) Competition is an annual event in synthetic biology. Teams participating in iGEM typically spend several months conducting research, designing their projects, and building their biological systems. These projects can range from addressing real-world problems in areas such as healthcare, environmental sustainability, and manufacturing, to ...
Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespin’s annual laboratory testing capacity. Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond Young, would receive large numbers of patient samples from hospitals containing cancer cells so that the researchers could analyze them, Pak says. One major challenge they faced was that some of the samples, which were derived ...
Hu’s group is particularly useful for TB diagnosis in infants and young children, given its ability to diagnose TB using small volume serum samples that can be readily obtained from this population. Tony Hu, Ph.D., professor and Weatherhead Presidential Chair in Biotechnology Innovation at the Tulane University School of Medicine stated, “The need for better methods ...
The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), with 70% of patient samples completely inactivated from a single 5-minute treatment. ...
The PCR methodology Methodology involves mixing in a closed tube the patient’s sample and the necessary building ingredients that under specific conditions can amplify a preselected portion of DNA/RNA sequence, if it is present in the patient’s sample. ...
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. The Series A2 round was led by the Washington Research Foundation along with ...
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. ...
By combining Northstar Select and Northstar Response, we aim to be the one-stop-solution for providers treating any late stage solid tumor cancer patient,” said Oguzhan Atay, PhD, co-founder and CEO of BillionToOne. ...
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows ...
Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for ...
Barriers associated with currently available methods, such as a colonoscopy or a stool-based test, can make the process unpleasant, time-consuming and difficult to complete.2 With a simple blood draw, the Shield test overcomes these barriers because it requires no special preparation, no sedation, no dietary changes, no extra time away from family or work, and it can be completed as part of any ...
The NOVEOS system requires only 4-μL sample size per test which reduce quantity not sufficient errors, resampling and patient trauma. ...
ARESid enables accurate and comprehensive detection and surveillance of bacterial and fungal microbes in a culture-free fashion directly from native patient specimen or environmental samples. Due to the semi-quantitative nature of ARESid, the sequencing and analysis service is equally suitable for pathogen detection and for microbiome profiling applications. ...
THE TECHNOLOGY TRANSFER IS ONGOING, WITH THE OBJECTIVE OF PROCESSING THE FIRST PATIENT SAMPLES EARLY Q2. “We are delighted to transfer our OncoDEEP technology to further enhance Synlab in the field of molecular diagnostics for clinical oncology,” stated Bernard Courtieu, CEO of OncoDNA. “Biomarker testing has the potential to improve ...
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...
Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive an upfront cash ...